Curated News
By: NewsRamp Editorial Staff
October 19, 2026
Tonix's TONMYA Fibromyalgia Data to Be Presented at IASP 2026
TLDR
- Tonix gains early scientific exposure for TONMYA at IASP 2026, reinforcing its first-in-15-years fibromyalgia leadership.
- Tonix will present a poster at IASP 2026 analyzing TONMYA's effects on fibromyalgia symptoms and physical function.
- Tonix's TONMYA research may improve fibromyalgia care by better understanding symptom relief and daily function.
- TONMYA, approved in August 2025 and launched in November 2025, is the first new fibromyalgia treatment in over 15 years.
Impact - Why it Matters
The presentation of TONMYA data at the IASP 2026 World Congress on Pain underscores the growing recognition of fibromyalgia as a serious condition and the need for new treatment options. As the first new therapy for fibromyalgia in over 15 years, TONMYA's presence at a global pain conference signals hope for millions of patients who have long faced limited choices. For investors, this visibility could enhance Tonix's credibility and market position, potentially driving adoption and future growth. Moreover, the company's broader pipeline in CNS and immunology, including programs for major depressive disorder, acute stress disorder, Prader-Willi syndrome, Lyme disease prophylaxis, and kidney transplant rejection, demonstrates a commitment to addressing high unmet medical needs. This news matters because it highlights a significant step forward in pain management and showcases a company poised to make a meaningful impact on patients' lives.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, has announced that a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain. The congress is scheduled for October 26-30, 2026, in Bangkok, Thailand. TONMYA received U.S. Food and Drug Administration approval on August 15, 2025, and was commercially launched in the United States on November 17, 2025. This presentation marks an important opportunity for Tonix to share data on its flagship medicine with the global pain research community.
TONMYA is the first new treatment for fibromyalgia in more than 15 years, addressing a significant unmet need for patients with this chronic pain condition. Tonix’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Investors and stakeholders can stay updated on Tonix’s latest news and developments through its newsroom at https://ibn.fm/TNXP. The announcement was distributed via TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies, which is part of the Dynamic Brand Portfolio @ IBN. TinyGems provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. For more information, visit https://www.TinyGems.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix's TONMYA Fibromyalgia Data to Be Presented at IASP 2026
